Michael E. Thase, MD
DELETE CME Institute Showcase
Developments in Major Depressive Disorder Therapy
August 14, 2023
Among the greatest unmet needs in MDD is for effective pharmacotherapies for patients who do not respond to first- and second-line antidepressant medications. After decades of muted progress, alternatives...
Academic Highlights
Patient Functioning, Life Engagement, and Treatment Goals in Major Depressive Disorder
September 7, 2022
Patients with MDD often report lack of motivation and energy and a feeling of disengagement from their own lives. Here, experts discuss treatment strategies that may be favorable for...
Insight videos
Patient Functioning and Life Engagement: Treatment Goals in Schizophrenia
August 17, 2022
Many people with schizophrenia feel isolated and disengaged from their own lives even when symptoms are under control. Here, experts discuss assessment of life engagement and treatment strategies that...
Academic Highlights
Patient Functioning, Life Engagement, and Treatment Goals in Schizophrenia
August 17, 2022
Many people with schizophrenia feel isolated and disengaged from their own lives even when symptoms are under control. Here, experts discuss assessment of life engagement and treatment strategies that...
Insight videos
Patient Functioning and Life Engagement: Unmet Needs in MDD and Schizophrenia
August 8, 2022
Besides achieving symptom relief and improved functioning, many patients with serious mental illness wish to connect more with others and feel engaged with their lives. Five experts discuss life...
Academic Highlights
Patient Functioning and Life Engagement: Unmet Needs in MDD and Schizophrenia
August 3, 2022
Besides achieving symptom relief and improved functioning, many patients with serious mental illness wish to connect more with others and feel engaged with their lives. Five experts discuss life...
Original Research
Adjunctive Pimavanserin and Sleep/Wakefulness in MDD
December 1, 2020
Adjunctive pimavanserin can reduce depressive symptoms and improve function in patients with major depression and inadequate antidepressant response. This analysis evaluated the effects of adjunctive pimavanserin on sleep/wakefulness disturbances.
Original Research
Utility of Combinatorial Pharmacogenomics in Depression
October 31, 2019
This study sought to ascertain the extent that pharmacogenetic testing can inform treatment decisions among patients with treatment-resistant depression whose medications are subject to gene-drug interactions—read the article to...
